Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
Horizon Therapeutics Public Price Performance
Shares of NASDAQ:HZNP traded down $2.53 during midday trading on Tuesday, reaching $67.12. 3,020,308 shares of the company traded hands, compared to its average volume of 2,062,524. The firm has a market cap of $15.46 billion, a PE ratio of 20.72, a PEG ratio of 1.46 and a beta of 1.12. The stock's 50-day simple moving average is $82.08 and its 200-day simple moving average is $93.13. Horizon Therapeutics Public has a 12 month low of $60.76 and a 12 month high of $120.54. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.79 and a current ratio of 4.05.
Horizon Therapeutics Public (NASDAQ:HZNP - Get Rating) last issued its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.36 by ($0.29). The company had revenue of $876.40 million for the quarter, compared to the consensus estimate of $938.82 million. Horizon Therapeutics Public had a net margin of 20.06% and a return on equity of 27.90%. The firm's revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.62 earnings per share. As a group, equities analysts anticipate that Horizon Therapeutics Public will post 5.08 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
HZNP has been the topic of several research analyst reports. The Goldman Sachs Group lowered their price objective on shares of Horizon Therapeutics Public from $164.00 to $144.00 and set a "buy" rating on the stock in a research note on Thursday, August 4th. UBS Group downgraded shares of Horizon Therapeutics Public from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $137.00 to $71.00 in a research note on Thursday, August 4th. SVB Leerink downgraded shares of Horizon Therapeutics Public from an "outperform" rating to a "market perform" rating in a research note on Thursday, August 4th. Oppenheimer restated a "buy" rating and issued a $140.00 price objective on shares of Horizon Therapeutics Public in a research note on Friday, July 8th. Finally, BMO Capital Markets lowered their price objective on shares of Horizon Therapeutics Public from $145.00 to $117.00 and set an "outperform" rating on the stock in a research note on Thursday, August 4th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $117.22.
Insider Activity
In other news, CEO Timothy P. Walbert sold 17,600 shares of the firm's stock in a transaction on Wednesday, May 11th. The stock was sold at an average price of $90.00, for a total value of $1,584,000.00. Following the completion of the sale, the chief executive officer now directly owns 460,549 shares in the company, valued at $41,449,410. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Timothy P. Walbert sold 25,000 shares of Horizon Therapeutics Public stock in a transaction dated Tuesday, May 31st. The stock was sold at an average price of $92.48, for a total value of $2,312,000.00. Following the completion of the sale, the chief executive officer now directly owns 435,549 shares in the company, valued at $40,279,571.52. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Timothy P. Walbert sold 17,600 shares of Horizon Therapeutics Public stock in a transaction dated Wednesday, May 11th. The stock was sold at an average price of $90.00, for a total value of $1,584,000.00. Following the completion of the sale, the chief executive officer now owns 460,549 shares of the company's stock, valued at $41,449,410. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 98,384 shares of company stock worth $8,934,633. 2.50% of the stock is owned by corporate insiders.
